These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

619 related articles for article (PubMed ID: 30194076)

  • 1. Whole-transcriptomic Profile of SK-MEL-3 Melanoma Cells Treated with the Histone Deacetylase Inhibitor: Trichostatin A.
    Mazzio EA; Soliman KFA
    Cancer Genomics Proteomics; 2018; 15(5):349-364. PubMed ID: 30194076
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma.
    Ramsdale R; Jorissen RN; Li FZ; Al-Obaidi S; Ward T; Sheppard KE; Bukczynska PE; Young RJ; Boyle SE; Shackleton M; Bollag G; Long GV; Tulchinsky E; Rizos H; Pearson RB; McArthur GA; Dhillon AS; Ferrao PT
    Sci Signal; 2015 Aug; 8(390):ra82. PubMed ID: 26286024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential expression of ABCB5 in BRAF inhibitor-resistant melanoma cell lines.
    Xiao J; Egger ME; McMasters KM; Hao H
    BMC Cancer; 2018 Jun; 18(1):675. PubMed ID: 29929490
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HDAC8 Regulates a Stress Response Pathway in Melanoma to Mediate Escape from BRAF Inhibitor Therapy.
    Emmons MF; Faião-Flores F; Sharma R; Thapa R; Messina JL; Becker JC; Schadendorf D; Seto E; Sondak VK; Koomen JM; Chen YA; Lau EK; Wan L; Licht JD; Smalley KSM
    Cancer Res; 2019 Jun; 79(11):2947-2961. PubMed ID: 30987999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protein Kinase CK2α Maintains Extracellular Signal-regulated Kinase (ERK) Activity in a CK2α Kinase-independent Manner to Promote Resistance to Inhibitors of RAF and MEK but Not ERK in BRAF Mutant Melanoma.
    Zhou B; Ritt DA; Morrison DK; Der CJ; Cox AD
    J Biol Chem; 2016 Aug; 291(34):17804-15. PubMed ID: 27226552
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An Acquired Vulnerability of Drug-Resistant Melanoma with Therapeutic Potential.
    Wang L; Leite de Oliveira R; Huijberts S; Bosdriesz E; Pencheva N; Brunen D; Bosma A; Song JY; Zevenhoven J; Los-de Vries GT; Horlings H; Nuijen B; Beijnen JH; Schellens JHM; Bernards R
    Cell; 2018 May; 173(6):1413-1425.e14. PubMed ID: 29754815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of trichostatin A, a histone deacetylase inhibitor, on the regulation of apoptosis in H-ras-transformed breast epithelial cells.
    Park H; Lee YJ; Kim TH; Lee J; Yoon S; Choi WS; Myung CS; Kim HS
    Int J Mol Med; 2008 Nov; 22(5):605-11. PubMed ID: 18949380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells.
    Jenkins MH; Croteau W; Mullins DW; Brinckerhoff CE
    Matrix Biol; 2015 Oct; 48():66-77. PubMed ID: 25989506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low inducible expression of p21Cip1 confers resistance to paclitaxel in BRAF mutant melanoma cells with acquired resistance to BRAF inhibitor.
    Jang GH; Kim NY; Lee M
    Mol Cell Biochem; 2015 Aug; 406(1-2):53-62. PubMed ID: 25912549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HTP Nutraceutical Screening for Histone Deacetylase Inhibitors and Effects of HDACis on Tumor-suppressing miRNAs by Trichostatin A and Grapeseed (Vitis vinifera) in HeLa cells.
    Mazzio EA; Soliman KF
    Cancer Genomics Proteomics; 2017 Jan; 14(1):17-33. PubMed ID: 28031235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BH3-mimetic gossypol-induced autophagic cell death in mutant BRAF melanoma cells with high expression of p21Cip¹.).
    Jang GH; Lee M
    Life Sci; 2014 Apr; 102(1):41-8. PubMed ID: 24625733
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells.
    Cesi G; Walbrecq G; Zimmer A; Kreis S; Haan C
    Mol Cancer; 2017 Jun; 16(1):102. PubMed ID: 28595656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.
    Hoeflich KP; Herter S; Tien J; Wong L; Berry L; Chan J; O'Brien C; Modrusan Z; Seshagiri S; Lackner M; Stern H; Choo E; Murray L; Friedman LS; Belvin M
    Cancer Res; 2009 Apr; 69(7):3042-51. PubMed ID: 19276360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aberrant modulation of ribosomal protein S6 phosphorylation confers acquired resistance to MAPK pathway inhibitors in BRAF-mutant melanoma.
    Gao MZ; Wang HB; Chen XL; Cao WT; Fu L; Li Y; Quan HT; Xie CY; Lou LG
    Acta Pharmacol Sin; 2019 Feb; 40(2):268-278. PubMed ID: 29777202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rescue of cell cycle progression in BRAF
    Toress-Collado AX; Nazarian R; Jazirehi AR
    Tumour Biol; 2017 Sep; 39(9):1010428317721620. PubMed ID: 28936920
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Upregulation of MicroRNA-1246 Is Associated with BRAF Inhibitor Resistance in Melanoma Cells with Mutant BRAF.
    Kim JH; Ahn JH; Lee M
    Cancer Res Treat; 2017 Oct; 49(4):947-959. PubMed ID: 28052651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vorinostat in patients with resistant
    Huijberts S; Wang L; de Oliveira RL; Rosing H; Nuijen B; Beijnen J; Bernards R; Schellens J; Wilgenhof S
    Future Oncol; 2020 Apr; 16(11):619-629. PubMed ID: 32125175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Receptor-Driven ERK Pulses Reconfigure MAPK Signaling and Enable Persistence of Drug-Adapted BRAF-Mutant Melanoma Cells.
    Gerosa L; Chidley C; Fröhlich F; Sanchez G; Lim SK; Muhlich J; Chen JY; Vallabhaneni S; Baker GJ; Schapiro D; Atanasova MI; Chylek LA; Shi T; Yi L; Nicora CD; Claas A; Ng TSC; Kohler RH; Lauffenburger DA; Weissleder R; Miller MA; Qian WJ; Wiley HS; Sorger PK
    Cell Syst; 2020 Nov; 11(5):478-494.e9. PubMed ID: 33113355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trichostatin A, a histone deacetylase inhibitor, induces synergistic cytotoxicity with chemotherapy via suppression of Raf/MEK/ERK pathway in urothelial carcinoma.
    Lin WC; Hsu FS; Kuo KL; Liu SH; Shun CT; Shi CS; Chang HC; Tsai YC; Lin MC; Wu JT; Kuo Y; Chow PM; Liao SM; Yang SP; Hong JY; Huang KH
    J Mol Med (Berl); 2018 Dec; 96(12):1307-1318. PubMed ID: 30288546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncogenic BRAF and p53 Interplay in Melanoma Cells and the Effects of the HDAC Inhibitor ITF2357 (Givinostat).
    Celesia A; Franzò M; Di Liberto D; Lauricella M; Carlisi D; D'Anneo A; Notaro A; Allegra M; Giuliano M; Emanuele S
    Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.